Louis Allott, PhD
Director
Louis Allott is a translational radiochemist with 15 years' experience across academia, industry and the NHS. His work spans the full radiopharmaceutical development pathway, from the design and radiolabelling of novel tracers through automated synthesis development to GMP manufacture and first-in-human clinical translation.
Louis held research positions at the Institute of Cancer Research and Imperial College London, where as Chemistry Lead he developed new radiopharmaceutical technology. As Head of Radiochemistry at the University of Hull he led radiochemistry across the Positron Emission Tomography Research Centre and Molecular Imaging Research Centre, developing GMP radiotracer production and a research group focused on next-generation radiopharmaceuticals and theranostics. He has published 48 articles, secured £289k in research funding as principal investigator with a further £1.8m as co-investigator, and holds honorary appointments at King's College London and Hull University Teaching Hospitals NHS Trust.
Louis founded Radiopharmium in 2024 and works with clients including GE HealthCare, Daisy Medical Research Limited and Aptamer Group, where he serves as fractional Director of Radioligand Development and Scientific Advisory Board member. He brings expertise in FASTlab automation, radiopharmaceutical pipeline development and the strategic leadership of GMP manufacturing facilities.